Table 2.
Summary of IDH status in tumor and plasma for each patient.
| Patient No. | Histology (Grade) † |
Age/Current Disease Setting/Treatment History | Time From IDx to ctDNA (Months) | Tumor IHC IDH1-R132H |
Tumor NGS IDH1 (VAF) |
Plasma ctDNA BEAMing IDH1 (VAF)(RANO) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T3 | T4 | T5 | T6 | T7 | ||||||
| 1 | Astrocytoma (grade 4), IDH-mutant | 65/ND/SX→RT + TMZ→TMZ × 2→PD (Feb 2018) →Exitus 12 m postND |
2 | MUT |
R132H
(13.3%) |
- | NMD (PR; Post-SX) |
NMD (SD; Post-RT) |
- | - |
R132H (0.071%) (PD; 10-m post-SX) |
- |
| 2 | Glioblastoma, IDH-WT | 48/ND/SX→RT + TMZ→TMZ × 6→W&S→PD→SX→Exitus 12 m postND | 2 | WT | WT | NMD (SD; 2 m Post-RT) |
NMD (SD; 4 m Post-RT) |
- | NMD (PD; 7 m post-SX) |
NMD (PD; 9 m post-SX) |
NMD (PD; 10 m post-SX) |
NMD (PD; 12-m post-SX) |
| 3 | Astrocytoma (grade 3), IDH-mutant | 70/RD/SX (Jun 2015)→SX (2018)→TMZ × 12→W&S (Jan 2020)→SD (ongoing) | 36 | MUT |
R132H
(14.35%) |
NMD (PD; Pre-BX) |
NMD (SD; 1 m Post-BX) |
- | NMD (SD; Post 2nd TMZ) |
NMD (SD; Post 4th TMZ) |
NMD (SD; Post 5th TMZ) |
NMD (SD; Post 6th TMZ) |
| 4 | Astrocytoma (grade 4), IDH-mutant | 34/ND/SX (PR May 2018)→RT + TMZ→TMZ × 10→W&S (12 m)→TMZ × 2→SX (2021)→RT→PD (Oct 2021)→BEV (ongoing) | 1 | MUT |
R132H
(31.1%) |
R132H (0.377%) (ND; Pre-RT) |
NMD (Intra-RT) |
NMD (Intra-RT) |
NMD (1 m Post-RT) |
NMD (2 m Post-RT) |
NMD (PsPD; Post 2nd TMZ) | NMD (Post 3rd TMZ) |
| 5 | Glioblastoma, IDH-WT | 50/ND/SX→Exitus 2 m post-SX | 0 | WT | WT | NMD (ND; Pre-BX) |
- | - | - | - | - | - |
| 6 | Glioblastoma, IDH-WT | 55/RD/SX (2013)→RT + TMZ→TMZ × 6→SX (RD; 2017)→TMZ × 6→W&S (6 m)→BEV × 6 m→Exitus 6y postND | 48 | WT | WT | NMD (RD; Pre-SX) |
NMD (RD; Pre-SX) |
- | - | - | - | - |
| 7 | Glioblastoma, IDH-WT | 72/ND/SX (2017)→RT + TMZ→TMZ × 3→SD→W&S (SD ongoing) | 0 | WT | WT | NMD (PD; Pre-SX) |
NMD (PD; Pre-RT) |
NMD (PsPD; 1 m Post-RT) |
- | - | - | - |
| 8 | Astrocytoma (grade 2), IDH-mutant | 34/RD/SX (2015)→RT + TMZ→TMZ ×→SX (RD; 2017)→BEV × 30→PD→Exitus 38 m postND | 26 | WT |
R132G
(20.5%) |
NMD (PR; Post-SX) |
- | - | - | - | - | - |
| 9 | Oligodendroglioma (grade 2), IDH-mutant, and 1p/19q-codeleted | 58/RD2/SX (ND; 2004)→SX (RD1; 2011)→RT (RD2; 2017)→TMZ × 6→W&S→PD & lost to FU in Jan 2020 | 156 | MUT |
R132H
(44.8%) R132C (0.75%) |
NMD (PD; Pre-RT) |
R132C (0.025%) (SD *; 5 m Post-RT) |
NMD (SD *; 11 m Post-RT) |
- | - | - | - |
| 10 | Astrocytoma (grade 4), IDH-mutant | 78/ND/SX (2018)→RT + TMZ→TMZ × 3→PD→Exitus 7-m postSX | 0 | WT |
R132H
(5.9%) |
NMD (ND; Pre-BX) |
- | - | - | - | - | - |
Astro: astrocytoma, BEAMing: beads, emulsion, amplification and magnetics, BX: biopsy, ctDNA: circulating tumor DNA, GBM: glioblastoma multiforme, IDx: initial diagnosis, IHC: immunohistochemistry, MUT: mutant, ND: new diagnosis, NMD: no mutation detected, NGS: next generation sequencing, Oligo: oligodendroglioma, PD: progressive disease, PR: partial response, RANO: response assessment in neuro-oncology criteria, RD: recurrent disease, RD1: first RD, RD2: second RD, RT: radiotherapy, SX: surgery, T: time at which blood was drawn for ctDNA analysis, VAF: variant allele frequency, W&S: wait and see strategy, WT: wild-type. Blue indicates mutations in tumor tissue. Red indicates mutations in ctDNA. Black bold indicates tumor-NGS IDH1+ patients with ND or showing PD on MRI. (-) indicates either not performed or not applicable. † According to the 5th edition of the WHO classification of tumors of the CNS. * Patient with a paradoxical response to RT, with stable disease of the irradiated lesion and PD at the anteromedial surgical margin.